Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer
NCT03414684Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in triple-negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03414684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414684.